

Advanced Strategies Against COVID-19

Review

Maged Naser¹, Mohamed MN², and Lamia H. Shehata³

¹Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of ob/gyn,

²King Fahd Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Surgery,

³Care National hospital, Department of Radiology.



Abstract – The arising SARS-CoV-2 viral disease (COVID-19) has caused a worldwide health alert because of its high rate of infection and mortality in people with chronic cardiovascular comorbidities, as well as creating complex clinical conditions. This has constrained mainstream researchers to investigate various techniques that permit combating this viral disease just as treating hazardous fundamental impact of the infection on the individual. In this work, we have evaluated the latest logical proof to give an extensive display in regards to the biotechnological techniques that have been proposed to combat this new viral disease. We have focused in our study on vaccine production, nanotechnology applications, repurposing of known drugs for unrelated pathologies, and the search for bioactive molecules acquired from natural products. The objectives incorporate safely use as possible prophylactic or therapeutic treatment, in view of in silico and in vivo studies, including clinical trials around the world for the right and ideal diagnosis of the infection. This study intends to feature the advancement of groundbreaking thoughts that can diminish the time line for research yield and improve research quality while simultaneously, remembering the efficacy and safety of these potential biotechnological strategies.

Keywords – COVID-19, Antivirals, Drugs and COVID-19, Vaccines against COVID-19, Nanotechnology against COVID19.

I. INTRODUCTION

In the late 2019, a group of patients with abnormal pneumonia was analyzed in Wuhan, China [1], and the etiological agent was confined and its genome sequenced, which was discovered to be a rising zoonotic infection, individual from the Corona viridae family, genetically related, Severe acute respiratory disorder Covid (SARS-CoV) [1,2]. The epic developing infection named SARS-CoV-2 displays a fast human-to-human spreading through the respiratory tract, and is responsible of a condition known as Coronavirus disease of 2019 (COVID19) [3]. COVID-19 has become a pandemic episode with more than 72.196 million individuals tested positive for the infection, which has brought about more than 1.6 million deaths around the world by mid-December 2020[4] As per data showed on the World Health Organization (WHO) COVID-19 Dashboard, even in nations where the quantity of every day cases has dropped (e.g., China, Australia), it is beyond the realm of imagination to expect to say that the infection has vanished since active cases are as yet revealed day by day. For example, in districts like Europe and North America, and agreeing with the autumn and winter seasons, an emotional expansion in the quantity of revealed cases has constrained a few nations (for example Italy, France, Germany) to fix clean limitations. In any case, in nations where the circumstance has improved (for example Chile), expansive consistent testing, surveillance and contact tracing are still active.

The SARS-CoV-2 infection clinical manifestation is complex; differing from asymptomatic or gentle manifestations in over 80% of carrier people, to serious respiratory and systemic distress, including obstructive pneumonia, hypoxia, favorable to inflammatory

cytokine storm, coagulopathies, neurocardiovascular issues, and death. The mortality rate ranges from 1 to 3% among symptomatic patients, contingent upon medical infrastructure and early clinical intervention [5 -10]

Disease severity varieties among infected patients are related to the individual vulnerability, principally controlled by the density of the viral cell receptor, angiotensin-converting enzyme II (ACE2). This is fundamentally higher in people more established than 50 years, or patients with constant neurocardiovascular comorbidities, for example, diabetes mellitus, hypertension, and obesity [6,11].

Right up 'til the present time, neither specific prophylactic nor therapeutic treatment, including antiviral medications or molecules to diminish severe symptoms, are accessible, given the novelty of SARSCoV-2, and the absence of regulatory affirmed medicines for other Covid and related diseases. Thusly, and given the requirement for fast improvement of powerful chemotherapeutic mixtures for COVID-19 treatment, the current methodology has been the repurposing of existing medications utilized in disconnected pathologies, particularly those that need significant results before.

These repurposed drugs have been investigated with the expectation to impede or hinder viral disease or to adjust neurotic hyperinflammatory reactions [12,13]. The reapplication of these medications has been upheld by in silico approaches, hindrance of SARS-CoV-2 or related Covid infection in tissue culture and animal models, or pharmacological application in SARS-CoV, or random immunopathologies such rheumatoid joint inflammation, lupus, or bacterial sepsis. In a comparable methodology, several current reports propose the utilization of natural substances as complementary prophylactic or therapeutic antiviral against COVID-19 that have shown adequacy against other Covies related with SARS-CoV-2. Another technique for the orderly fight against the novel COVID-19 protective anti- SARS-CoV-2 immunoresponses and long-lasting memory. In this sense, Nanotechnology and new materials are other open fronts in the anticipation, location and immunization approach against COVID19 infection.

Here, we survey the latest biotechnological propels in such manner and assess the most encouraging remedial methodologies for the COVID-19 anticipation and treatment. Simultaneously, we present a portion of the possible current and future challenges affronting effective therapeutic approaches and diagnostics around the world.

II. GENERALITIES OF THE SARS-COV-2 INFECTION AND PHASES OF THE INFECTION

Coronaviruses are single-stranded RNA (ssRNA) enveloped viruses with a progression of distending glycoproteins, called spike protein (S) [1]. Infection of the susceptible cell infection begins with absorption of the virus through its S-protein to the cell surface ACE2 receptor, followed by proteolytic activation of S-protein fusogenic area by host transmembrane serine protease 2 (TMPRSS-2). On the other hand, the virus can enter the cell by endocytosis and acidification of the endolysosome [14,11,15] Endless supply of viral ssRNA, the 5' locales (orf1a and orf1b) of long genome are made an interpretation of by ribosomes into two enormous covering polypeptides, pp1a and pp1ab, which are then proteolytically handled by two virally encoded proteases, the chymotrypsin-3-like protease (3CLpro) and the papain-like protease (PLpro), bringing about 16 functional non-structural proteins (NSP-1-16)[16,17] . These delivered viral NSPs are responsible for inactivating host cell characteristic antiviral reactions and establishing the environment for viral replication. The replication complex, an RNA-dependent RNA polymerase (RdRNAPol) formed by NS7/8/12, catalyzes both transcription of underlying genes and replication of the viral genome [18].

Essential for virus, RdRNAPol has arisen as the principle antiviral drug target, essentially through wide range incipient chain-eliminator nucleoside analogs. Regardless, NSP14-exonuclease gives resistance from the antiviral Ribavirin, by eliminating it from slowed down replicative chain [19]. Viral replication takes place in double- membrane organelles, where genome is bundled by nucleoproteins (N) shaping a nucleocapsid that leaves the cell by means of the exocytosis pathways, and by maturing through the cell layer gaining the lipid envelop and S-glycoproteins [20].

The noticed natural history of the clinical infection in humans incorporate two phases, (I) a mid 5–7-day post-exposure asymptomatic period, where SARS-CoV-2 infects the upper respiratory epithelium prompting an evident suppression of inflammatory reaction by the host, followed by (ii) an aspiratory disease that can bring about mild or severe pneumonia. A portion in this later group can progress to (iii) a hyperinflammatory phase (> 7 days) that starts with disease of the alveolar epithelium, which has a higher density of ACE2 viral receptor, bringing about an enhanced infection triggering the expression of a wide range of pro-inflammatory cytokines [21,22]. These reactions are responsible for leukocyte invasion, proteinaceous-liquid accumulation, and obstruction of the alveoli, and thus, gas exchange failure and hypoxia [22].

Furthermore, a systemic spread of the infection brings about extra susceptible, ACE2-expressing, tissue infection, including cardiovascular epithelium, heart, liver, kidney and intestinal linings [14]. In such manner, gene expression of ACE2 on the cardiovascular epithelium surface is surprisingly enhanced by interferon-mediated reactions to the SARS-CoV-2 in the lungs; and therefore, expanding systemic scattering of the disease to extrapulmonary tissues [23].

The systemic infection, along with enhanced inflammatory reactions, is most likely capable of the coagulopathies observed in some individuals, just as viral septic shock and multi-organ failure that outcomes in high mortality without clinical intervention [5,24,8,9,10,25,23].

The pathways that actuate incendiary reactions fluctuates altogether among infected patients, notwithstanding, among the most significant cytokines related to serious pathologies are $\text{INF-}\gamma$, $\text{IL-1}\beta$, IL-18 , while two specific pointers of progression and severity of COVID-19 pathology are $\text{TNF-}\alpha$ and IL-6 . These uncontrolled favorable to provocative cytokines are apparently the primary liable for the acute respiratory distress (ARDS), cytokine storm condition, viral sepsis and multiorgan failure, and subsequent death.

III. VACCINES AGAINST COVID-19: A BIOTECHNOLOGICAL RACE

One of the difficulties during a novel pandemic is the improvement of an effective and safe immunization, to empower an individual's immune system to make its own neutralizing antibodies against a pathogen. This antibody would produce "herd immunity" in a population of susceptible people, without risking their lives. In such manner, in spite of the fact that SARS-CoV-2 was at first seen as a high transmission rate disease, late epidemiological seroconversion information in nations that didn't matter approaches of required population confinement, like the instance of Sweden, shows that only 7.3% of its population carries antibodies against SARS-CoV-2 [26]. Accordingly, natural effective "herd immunity" of over 60% of the Swedish population would require years of continuous spread of the virus, with the related medical challenges. These information feature the significance and earnestness for a powerful immunization improvement, which can produce defensive invulnerability in susceptible people and lessen the spread of the infection, finishing compulsory restriction which can possibly worsen financial issues around the globe, especially in agricultural nations. In like manner, research on a prophylactic COVID-19 immunization has started in numerous organizations and scholastic establishments. The ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) is a community program that looks to trade all the got data from the turn of events and testing of creating immunizations, to crush the new Covid and the disease it causes [27]. An enormous bunch of immunization engineers, controllers, researchers, and general public health specialists who went to the 11–12 February Global Research and Innovation Forum, expressed that "We will just stop COVID-19 through fortitude," and "Our common responsibility is to guarantee all individuals approach every one of the tools to prevent, identify, treat and defeat COVID-19", as per the World Health Organization (WHO) Director-General [28].

Albeit an antibody against SARS-CoV was developed, the generation of anti- SARS-CoV-2 immunization is on course [29]. Covids share structures, which incorporate spike (S1 and S2), layer (M), envelope (E), and nucleocapsid (N) proteins, that could give applicable antigenic targets [30]. Among these primary proteins, the S-protein contains the determinant structure for virus passage, and subsequently, antibodies coordinated against it, especially the receptor-binding domain (RBD) or the fusogenic area, should effectively block the virus access to susceptible cells. Notwithstanding, the SARS-CoV-2 S-protein amino acid sequences differ from that of SARS-CoV in a several areas basic for protective immunity. These remember three extra short inclusions for the N-terminal space (NTR, area A) and the C-terminal locale (CTR, areas B, C, and D), and four out of five key buildups changes in the RBD receptor-restricting theme [31].

Adjusting the S1. Then again, the S2 subunit shapes the spike protein branch, and contains two heptad rehashes areas (HR1 and HR2) [32], like other enveloped viruses. The communication of HR2 found NTR, and HR1 situated CTR, structures a six-helix pack structure in which HR2 districts accumulate into the spaces framed by the trimeric HR1 snaked curl [33].

Existing proof propose that the SARS-CoV-2 S-protein ties human ACE2 with higher proclivity (10–20-overlay) contrasted with the S-protein of SARS-CoV, which is related to an all the more promptly transmission structure human to human [17].

Vaccine development is a prolonged process (development, animal model testing and clinical trials, assessment of safety, regulatory considerations) that regularly requires years with high economic costs. Given the criticalness despite the current pandemic, a sped-up improvement was proposed to deliver a successful vaccine within 12–18 months [34]; consequently, several recently utilized and novel platform advances for quick and safe immunization plan and assembling were picked. These techniques comprise of a platform-based delivery approach that is flexible for the modularization of target pathogens antigenic parts and

upgrade their immunogenicity [35]. For SARS-CoV-2, a several systems previously tried in animals' models for prophylactic protection against related MERS and SARS-CoV seem, by all accounts, to be the main candidates. The principal platforms used are centered around traditional complete however attenuated virus strategy, complete recombinant antigenic viral proteins as subunit antibody (fundamentally the S-protein or specific epitopes from its RBD), or as a component of adenoviral vector, lastly novel nucleic acid (DNA, mRNA) delivery technology.

Other studies indicate that supermolecule vaccines platforms have major benefits, on quickly committal to writing for microorganism proteins expression within the context of human cells, which may induce effective prophylactic host immune responses, albeit, important analysis during this output is required [36].

In terms of progress, Moderna and CanSino Biologics were the primary to start clinical trials for vaccines against COVID-19 [37], however BioNTech has consecutive calculable completion (genus Medicago and Novavax use a virus-like particle (VLP) platform as scaffolds to gift the SARS-CoV-2 S-protein, the second alongside their proprietary adjuvant Matrix-M [38]. Countries like Egypt, Kingdom of The Netherlands, Mexico, Greece, Colombia, US, and Australia, square measure presently developing vaccines supported the Bacillus Calmette–Guerin (BCG),

A method antecedently according to supply broad protection against alternative metabolic process infections. additionally, supporting this repurposing, countries that have a late begin of universal BCG policy had seen high mortality, in keeping with the thought that BCG protects the immunized people, and notably, the aged population [39,40].

The Brazilian National regulatory authority approved Sinovac Biotech Ltd. immunogen generated from attenuated virus, for a phase III clinical trial clinical study [41]. Oxford and Astra Zeneca passed with great ape adenovirus-vectored immunogen (ChAdOx1 nCoV-19) known as AZD1222, which may generate a fast protein and lymph cell responses against SARS-CoV-2 [42]. Biotech's BNT162 immunogen from ribonucleic acid induces positive responses manufacturing antibodies in volunteers [43]. though Moderna (mRNA-1273) was the primary company set into human trials for a COVID-19 immunogen, in 2020, Chinese military approved CanSino Biologics known as Ad5 for phase III clinical trial protocols, results support immunogen effectiveness against a five $\times$ 10¹⁰ microorganism load administered to healthy adults [44].

Another way to get a short-lived passive protection is that the administration of specific opposed SARS-CoV-2 antibodies, derived from COVID-19 convalescent patient's plasma. Therapeutic administration of recuperation sera has to this point provided the foremost effective strategy to treat COVID-19 patients, preventing significant pathological damage associated with the infection; an empirical study of 245 patients with advance disease, recommend that the therapy is safe [45]. Moreover, it's been projected that COVID-19 convalescent sera may be used as a prophylactic measure for in close-contact people to stop infection, or to treat people with early or mild symptoms [46]. Currently, there are clinical trials in several countries developing treatments using convalescent plasma (NCT04333355 and NCT04358783, Mexico; NCT04403477, Bangladesh; NCT04344977, NCT04360278, and NCT04418518, US; NCT04342182, Netherlands; NCT04393727, Italy; NCT04292340, China; NCT04348656, Canada; NCT04425915, India; NCT04352751, Pakistan; NCT04375124, Turkey; NCT04347681, Arabia).

IV. THE START OF IMMUNIZATIONS

In December 2020, the mRNA-based immunogen developed by Pfizer and BioNTech (BNT162 vaccine) was approved by the Medicines and Health product regulatory authority (MHRA), once showing Associate in efficaciousness larger than ninety fifth in phase III clinical trial. By period of time, the USA Food and Drug (FDA) has approved emerging use authorization of this ribonucleic acid immunogen within the USA for people older than sixteen years, once verification of its safety by a committee of doctors. Similarly, to the current immunogen style, another ribonucleic acid immunogen developed by Moderna (mRNA-1273) offers a ninety-four efficaciousness [47] and is presently underneath review by the agency for licensing and application in immunization of the overall population. though showing terribly promising efficaciousness results, these vaccines, however notably the Pfizer and BioNTech style, needs uninterrupted cold (– seventy °C) chain demand [3], which might limit its implementation in less developed countries that lack the mandatory infrastructure for transportation and storage. additionally, reports of great hypersensitive reactions to the Pfizer and BioNTech immunogen by people with history of robust food allergies would need any investigation.

various vaccines supported animal virus that have shown beyond ninetieth protecting efficaciousness in phase III clinical trial, like those developed by Oxford-Astra Zeneca and Gamaleya Russian Center [48].

V. NANOTECHNOLOGY AS THERAPEUTIC STRATEGY AGAINST COVID-19

Since the 1980s, nanotechnology and nanoscience are offering a number of approaches to cope with different challenges, including the actual COVID-19 pandemic, based on an abundance of engineered materials identifiable by their useful physicochemical properties through versatile chemical functionalization, in addition to the vaccine development [49]. Furthermore, the development of nanomaterials with antimicrobial properties, called nano antimicrobials, is an ongoing work for the last 16 years [50].

Nanotechnology and new materials are used against COVID-19, as LV SMENP DC vaccine, developed by Shenzhen Geno-Immune Medical Institute which modified dendritic cells with lentivirus vectors expressing SARS-CoV-2, engineering a synthetic vaccine including SARS-CoV-2 minigene and immune modulatory genes [30]. University of Washington, another replicon RNA vaccine is under study, formulated with Lipid Inorganic Nanoparticles (LION/ repRNA-CoV2S) to induce rapid immune protection against SARS-CoV-2 infection, which will enter clinical development under the name HDT-301[51]. Another strategy for vaccine development is the administration of gold nanoparticles (Au NP) conjugated with viral antigens, achieving higher IFN- γ concentrations in mice, immunized with Au NPs conjugated with antigens from swine transmissible gastroenteritis virus [52].

VI. NANOMATERIAL-BASED IMMUNE APPROACHES

Different strategies in which nanomaterials can assist regulating the immune system, in an antigen-specific manner, through immune-targeted nanotherapeutics within the vaccination context, including either direct administration of viral antigens, or molecules such as DNA or RNA [49]. For instance, it has been suggested that the use of nanoparticles coupled with SARS-CoV-2 S-glycoprotein can induce a precise antibody response against this pathogen, using a mouse model [53], nanoparticles protect the antigen's local construction, and improves conveyance and introduction to the antigen-introducing cells. Other strategy studied for COVID-19 treatment is the employment of Mesenchymal Stem Cells (MSCs) derived exosomes, which used for various diseases treatments, such as lung, pancreatic, and breast cancers, Alzheimer's disease, among others, with the advantage that exosomes could prevent cytokines storm, and promote cellular repair [54,55].

Another prophylactic immunization is the aforementioned therapeutic administration of specific neutralizing antibodies (mainly IgG), directed specifically against SARS-CoV-2 RBD of S-protein found in serum from convalescent individuals. several hospitals around the world have started to treat severe cases of COVID-19 with transfusion of convalescent plasma (CP), due to the lack of effective antiviral treatments.

This strategy is not clear, given lack of randomized placebo double-blind studies. Supporting the purposed positive effect of platelet concentrate transfusion, a recent report by Mayo Clinic [56] analyzed the 7-day mortality among 35,370 hospitalized COVID-19 patients receiving this treatment (57% of which were severe patients and 25% where in artificial ventilators), this study observed a mortality reduction depending early post-diagnosis intervention was applied, in addition to the concentration of plasma IgG in platelet concentrate. Patients received platelet concentrate transfusion 3 or 4 days after diagnosis had 8% mortality, and 11.5% mortality, respectively. Similar decrease of mortality was observed among patients that received plasma with high IgG, compared to those that received a lower IgG titer. Given different antibodies concentration present in convalescent patients, an alternative could be the design and development of recombinantly synthesized engineered therapeutic antibodies, commonly known as nanobodies.

Another approach is the use of chimeric nanobodiesFc (where variable region of nanobody is fused to Fc of human immunoglobulin). Two recent reports demonstrated that neutralizing nanobodies applied at low concentration (4–18 nM) significantly decreased the number of viral plaque formation upon infection in tissue culture, by effectively binding to SARS-CoV-2 S-protein RBD (Receptor-Binding Domain) and blocking binding to ACE2 receptor [57,58].

VII. VIRAL INACTIVATION BY NANOMATERIALS

Different challenges remain using nanomaterials for clinical applications of polymers, oligomers, and small molecules candidates for SARS-CoV-2 clinical application. the resulting dilution upon treatment application to the host, results in efficacy loss as the viral complex dissociates, a limitation that can be overcome by synthesizing nanoparticles, which can irreversibly inhibit viral infectivity, permanently damaging the virion [49].

Several approaches have been studied as viral inactivators, including cellular nano sponges [59], human cell-derived membrane structures created as a medical countermeasure against coronavirus. The nano sponges are coated with receptors (such as ACE2—angiotensin-converting enzyme 2—, TMPRSS-2—transmembrane serine protease 2—and DPP4—dipeptidyl peptidase IV—, expressed on endothelial surfaces) necessary for viral adhesion and cellular entry, and inhibit viral interaction with the cellular surface, and hence, cellular invasion. Results showed a dose-dependent inhibitory effect on viral adhesion to cultured cells, rendering coronaviruses unable to infect their usual cellular targets [59].

This approach takes into account that although SARS-CoV-2 mainly targets the respiratory tract, it can also affect other organs (including gut, kidney), and even, the vascular system [49], ACE2 is a good candidate for this strategy, due to its wide expression in endothelial tissues.

VIII. NANOMATERIALS AS A PREVENTING STRATEGY TO PREVENT SARS-CoV-2 INFECTION

SARS-CoV-2 can infect new hosts, not just through direct contact with aerosols from infected people, yet additionally through contact with surfaces exposed to the pathogen, where the infection has been appeared to get by for as long as 3 days, contingent upon the surface type [60]. Thus, one of the areas of interest is the prevention of surface viral contamination.

For example, where polyvinyl alcohol (PVA) nanofibers were utilized to channel encompassing mist concentrates [61].

Charged PVDF multi-facet nanofiber channels, as a methodology against the airborne novel (COVID-19) with monodispersed NaCl nano-aerosol, getting up to 99% filtration effectiveness yields (comparative for N98 guidelines), utilizing PVDF 6-layer charged nanofiber channels in contrast with the 70.6% proficiency recently got [62]. Moreover, other than its uses for viral recognition, graphene has end up being a decent possibility to capture the SARS-CoV-2 infection [63].

Albeit restricted, there is work in regards to the treatment of Personal Protective Equipment (PPE) with charged metallic (like Cu, Ag, Fe, Zn among others) nanoparticles, which appears to bring about the arrival of antiviral agents (i.e., reactive oxygen species). For example, Ag-covered nanoparticles repress viral entry in host cells, by means of interactions with cell receptors [50]. Furthermore, nanotechnology has been applied in food safety, utilizing of nanofibers, nano emulsions, nano encapsulated materials among others, by exploiting the benefit of nanomaterials to interact with 60–600 nm particles. It is felt that nanoscale materials, under controlled delivery, could be valuable to prevent SARS-CoV-2 contamination of both, food products, and packaging materials [64].

IX. REPURPOSING OF KNOWN MEDICATIONS AGAINST COVID-19

As to COVID-19 pharmacological treatment, as of recently, just an exceptionally set number of specific anti- SARS-CoV-2 compounds (redesigned or developed) are available. Be that as it may, the most well-known procedure to distinguish useful drugs to reduce severe symptoms has been the repurposing existing drugs against unrelated diseases, particularly those safely utilized previously, regardless of whether not as antiviral. Since the WHO pronounced the COVID-19 as pandemic, numerous studies about the repurposing of known drugs have showed up. The methodologies utilized in silico, in vitro and in vivo contemplates, both in cell culture and animal models, and probably the most encouraging drugs have gone through clinical trials to test efficacy in diminishing viral burden, hospitalization time, severity and mortality of the infection.

These anti- SARS-CoV-2 chose drugs, focuses on a several cell processes or viral chemicals, including viral restricting to the receptor or entry into the susceptible cell and release of the genetic material, M star and PLpro protease activity, and the most promising up until now, inhibitors of the RdRpol, including the two nucleosides-analogs and non-nucleoside analog compounds or immunomodulation of early genetic or cell responses against the infection.

By mid-March, 24 continuous clinical trials were at clinical stages 2–4. In those trials, the following known drugs were considered: arbidol (umifenovir), bevacizumab, bromhexine, carrimycin, chloroquine, cobicistat, danoprevir, darunavir, favipiravir, fingolimod, human immunoglobulin, hydroxychloroquine, interferons, lopinavir, methylprednisolone, oseltamivir, pirfenidone, remdesivir, ritonavir, thalidomide, nutrient C and xianping [65].

Right around 12,000 realized drugs were analyzed in a largescale re-purposing overview, in vitro in Vero E6 cells, from which 30 were recognized, including some US Food and Drugs Administration (FDA)- affirmed drugs, which showed antiviral movement against SARS-CoV-2. From these atoms, the most encouraging were acitretin, apilimod, astemizole, clofazimine, hanfangchin A,

pagoclone, tretinoin, zaleplon GR, AL 3151, AQ-13, DL 28,170, MLN-3897 (AVE-9897), ONO 5334, SL-11128, VBY-825, YH-1238, ZK-93426 and Z LVG CHN2 [66].

An underlying in vitro study utilizing just FDA-endorsed drugs showed that amodiaquine, chloroquine, chlorpromazine, hydroxychloroquine, imatinib, and mefloquine have activity against SARS-CoV-2 at non-cytotoxic levels, including the drug β -d-N4-hydroxycytidine, and its orally bioavailable prodrug β -d-N4-hydroxycytidine-5'-isopropyl ester (Molnupiravir), were effective against remdesivir-resistant viruses and other zoonotic CoVs [67,68]. At present there are two going through stage 3 clinical trials in hospitalized and non-hospitalized adult patients to determinate the efficacy and safety of Molnupiravir [69].

Considering the possible synergism between drugs with anti-viral action tried independently (monotherapy), a few studies have been conducted. A primer clinical study conducted in 80 patients brought up that a blend of favipiravir with interferon (IFN)- α , showed preferable reaction and viral clearance than a combination of lopinavir, ritonavir and interferon (IFN)- α , on COVID-19 [70]. Also, a stage II preliminary including 127 adult patients showed that the combination of ribavirin, interferon beta-1b and lopinavir-ritonavir decreased the viral burden, the ideal opportunity for alleviating the symptoms and hospitalization [71]. Be that as it may, the mix of medications not generally builds the action, as it was exhibited in another investigation created in 50 patients where a monotherapy with arbidol was more effective at wiping out the viral burden at day 14 after confirmation, than a consolidated treatment with lopinavir-ritonavir [2]. At last, the preliminaries utilizing the consolidated treatment with lopinavir-ritonavir in hospitalized patients were stopped by WHO at early July. It has as of late been declared by a Japan Chemical Company, that Favipiravir has met the essential end point in stage III clinical preliminary directed in 156 COVID-19-positive patients with non-serious pneumonia, with a shorter time of resolution [72]. In view of this outcomes, the Chilean Ministry of Health has endorsed the importation of this medication, utilized in Russia, Turkey and different nations, at demand from certain Hospitals and the preliminary is in progress. Notwithstanding, is has been called attention to that Favipiravir increment uric acid levels in plasma [73].

An alternate way to deal with treat COVID-19 is to focus on the immediate elimination of the virus, by blocking the virus-host interaction by means of locking some host proteins utilized by the virus to interact with them. Those proteins have become the objective of known drugs, distinguishing, in vitro, just about 70 drugs, some of them FDA endorsed and the rest in clinical or preclinical stage. The last incorporate clemastine, cloperastine, haloperidol, hydroxychloroquine, progesterone, siramesine, ternatin-4, zotatifin, PB28, PD-144418 and PS3061, which were the most extraordinary drugs agreeing with such activities, in spite of the fact that it is essential to underline that PB28 arose as the most encouraging drug. In any case, alert ought to be taken with the utilization of cloperastine and clemastine, because of their possible results. It was additionally brought up that the notable drug dextromethorphan showed favorable to viral action [74].

The utilization of chloroquine for the treatment of COVID19 was in light of an activity of the State Council of China.

In an underlying in vitro study, hydroxychloroquine showed better anti-SARS-CoV-2 activity than chloroquine, and a few preliminaries directed in patients revealed a decrease in the recovery time, however the proof was restricted [75]. The FDA approved the crisis utilization of the chloroquine and hydroxychloroquine drugs before the end of March, in any case, because of the presence of various unfavorable occasions in patients treated with the referenced drugs, a pharmacovigilance reminder was produced by mid-May, as notice, about the unfriendly occasion in the setting of COVID19 [76]. Besides, SARS-CoV-2 passage in the pneumonic determined cell line Calu-3 was not blocked by chloroquine [77], recommending that the viral entry into lung cells can be through activation by TMPRSS-2 and not endocytosis, as it was recently proposed on the Caco-2 intestinal cell line.

A drug that has shown reliable and viable antiviral action, in vitro, against animal (counting human) Covids, even the SARS-CoV-2, is the exploratory, GS-444115 compound or remdesivir. This drug, recently developed to treat Ebola, was approved by the FDA under crisis use (FDA 2020) to treat COVID-19 taking all things together patients with severe disease. This drug has been related to various results, including rectal hemorrhages, diarrhea and liver damages. Besides, remdesivir isn't presently accessible for oral administration, and in this manner, intravenous application requires patient's hospitalization [78], confusing enormous scope utilization of remdesivir, likely mutations on the target viral enzyme, RdRpol complex or the related viral exonuclease, can hinder inhibitory impact by these nucleoside-analogue drugs, prompting the rise of drug resistant SARS-CoV-2 strains [79].

Nonetheless, an early preliminary directed in China with severe disease (normal age 65) showed no statistical differences when remdesivir was intravenously administrated. It ought to be referenced that clinical improvement was accomplished 5 days sooner, in average [22]. This recovery time improvement was likewise seen in a preliminary directed in 1063 patients (average age 59),

from various nations, where the average recovery time in the group of patients that got intravenous remdesivir was 11 days, compared with 15 days in the control group. What's more, death rate among patients getting remdesivir was 8%, against 11% in the standard treatment group, which, albeit not statically large, the study was ended right on time for moral reasons, because of the event of various evaluation unfavorable occasions [80]. Notwithstanding, in the last report of a similar exploration group, including 1062 adult patients (average 58 years) toward the beginning of October, they showed that when remdesivir was utilized in patients with lower respiratory tract infection, the recovery time was more limited. What's more, they called attention to that remdesivir may have prevented the progression to more severe disease and fewer days with oxygen [80].

Before the finish of October 2020, remdesivir was conceded formal endorsement by the FDA to be utilized in patients 12 years, and more established, and weight in any event 40 kg (FDA 2020). Nonetheless, the utilization of remdesivir stays questionable since a between time WHO Solidarity preliminary directed in 11,266 patients (81% under long term) around the world, showed that this drug didn't improve (or very little) patient's mortality, beginning ventilation nor hospitalization time [81].

It is realized that one of the principal difficulties found in patients with COVID-19, is the high incendiary reaction that causes disappointment in various organs, predominantly in the lungs, for which dexamethasone has been remembered for various drugs, with the plan to improve recuperation in patients with intense respiratory trouble. In a 2018 investigation of 277 intensive care unit patients, however distributed as of late, it was tracked down that early utilization of dexamethasone assisted with diminishing both mortality and the quantity of days for ventilator use. During this preliminary, the most well-known antagonistic occasion (around 70% of patients) was hyperglycemia [82].

The RECOVERY Collaborative (Group 2020) revealed comparative outcomes in an investigation with 6425 patients (mean 66 $\pm$ 15 years old), where an improvement was seen by day 28 of treatment, in patients utilizing mechanical ventilator. They reasoned that immunopathological issues ruled the underlying phase of the disease. As of late, the NIH proposed in its COVID-19 treatment rules the utilization of dexamethasone, both in hospitalized patients who need mechanical ventilators or oxygen alone, yet not in patients who don't require supplemental oxygen, and for those situations where dexamethasone isn't accessible, the NIH panel recommends the utilization of prednisone, methylprednisolone or hydrocortisone [83]. Comparative ends, lower 28-day mortality, were accomplished in an imminent meta-examination utilizing information structure 7 diverse clinical preliminaries where 1703 patients (middle age 60 years) with serious infection were treated with methylprednisolone, hydrocortisone or dexamethasone. Be that as it may, some unfavorable occasions happened [84].

Man-made reasoning and organization medication have assumed a fascinating part with regards to speeding up repurposing of known drugs against COVID-19. For instance, Mefuparib has been proposed by AI and factual investigation, to show a stronger antiviral movement than remdesivir. Also, Toremifene has been recognized, by network investigation, as great treatment for COVID-19 since it could obstruct the ACE2 and spike protein communication. Furthermore, some in vitro tests have shown the antiviral movement of this atom. Utilizing an organization-based approach, it was feasible to discover a mix of medications that could have likely movement against COVID-19, for example, dactinomycin–sirolimus, melatonin–mercaptopurine, emodin–toremifene and toremifene–melatonin. The last mix has been tried in a clinical preliminary in persistent with early disease [2].

X. NATURAL PRODUCTS AGAINST COVID-19

Medicinal herbs, just as bioactive substances that were extricated and purified from different plants, are promising sources for antiviral drugs. It is common for antiviral medicines to have accessible plans dependent on natural compound constructions. Among the classic models, we have homoharringtonine and emetine, got from the *Cephalotaxus* and *Psychotria ipecacuanha* plants, separately, which have anti-herpes virus properties and have successfully repressed SARS-CoV replication [85,86]. Quiet, practically 50% of the drugs affirmed somewhere in the range of 1981 and 2014 were determined or imitated a natural compound [87].

Then again, because of the urgency of compelling antiviral medicines against COVID-19, established researchers has been compelled to investigate each item that could safely be administered as prophylactic or therapeutic antiviral mixtures against SARS-CoV-2 disease. Furthermore, the investigation methodologies incorporate those completed not just in vivo with at least one biomolecule together, yet additionally those in silico contemplates. There are a several current reports that propose natural substances against COVID-19, which connect with previous studies revealing demonstrated efficacy against SARS CoV [88,86]. In like manner, given the current pandemic, the medical society is reusing different antiviral drugs, combing and joining them with biomolecules. For instance, the combination of the medication Tenofovir and Glycyrrhizin (natural compound) has been

concentrated as therapeutic or prophylactic mixes against Covid diseases [89]. In this unique circumstance, we gathered data on herbal formulation and mixtures determined and in silico concentrates from natural items that show therapeutic or prophylactic potential, as well as controlling and adding to the successful treatment against SARS-CoV-2.

XI. ADEQUACY AND CARE IN THE ADMINISTRATION OF HERBAL FORMULATION AGAINST COVID-19

In the current and real battle for COVID-19 control, the use of herbal formulation as complementary treatment has been another option; to control this disease, some natural products of ancient uses and generally of Chinese starting point have been as of late assessed and examined. Most herbal formulations are viewed as protected because of their long history of utilization for anticipation, treatment and control of different diseases, be that as it may, there are reports of toxicity, which can generally be because of misidentification and excess. Moreover, alert ought to be taken when there is no documentation of long recorded utilization of herbal mixtures [90].

It is essential to consider that COVID-19 produces distinctive clinical impacts and relies upon the progression of the disease [90], so a comprehensive treatment is important to dispose of disease impacts, like the presence of immune cells detachment, since their presence in blood increases the risk of an excessive immune response, straightforwardly prompting cytokine storms (a few patients create severe cardiovascular and kidney complications). Furthermore, those medicines should keep up intestinal homeostasis and protect intestinal wall barrier [91,92]. Hence, formulations or preparations dependent on medicinal herbs that can inhibit the various impacts and phases of the disease have been studied.

Studies reported formulations made by the progression of the disease that can keep up intestinal homeostasis and, repress IL-1 β production mediated by Toll receptors, and improve the expression of IL-10. The details utilized were: for mild disease stage: *Pogostemon Cablin* (Blanco), *Atractylodes Lancea* (Tunb.) Dc., *Scutellariae Radix*, *Chaihu Radix Bupleuri*, *Forsythiae Fructus*; for moderate stage: *Gypsum*, *Atractylodes Lancea* (Tunb.) Dc., *Polygoni Cuspidati Rhizoma Et Radix*, *Pogostemon Cablin* (Blanco), *Verbenae Herb*; for serious stage: *Ephedra Herba*, *gypsum*, *Lepidii Semen Descurainiae Semen*, buffalo horn; for critical stage: *Panax Ginseng* C. A. Mey., *Aconiti Lateralis Radix Praeparata*; and for recovery stage: *Hedysarum Multijugum Maxim.*, *Ophiopogon japonicus* (Linn. f.) Ker-Gawl, *Panacis Quinquefolii Radix*. Besides, they show that kaempferol, beta-sitosterol, stigmaterol, quercetin, luteolin, genkwanin, diop, and isorhamnetin took an interest in at least three infection stages. A clinical report on 54 patients with COVID-19, treated with these natural blends tracked down a positive reaction in the recovery and improvement of patients, and recommended the significance of regulating intestinal function and maintaining microenvironmental balance during treatment [91]. This is potentially on the grounds that QFP [92] is incorporated inside the assessed treatment, and as indicated by an unreasonable utilization of this natural blend can cause epigastric distress, diarrhea, and surprisingly hypertension [93].

Another plan contemplated was Ma Xing Shu Gan Decoction. The essential remedy is made out of the accompanying spice species: 6 grams of *Herba ephedrae* (MH), 9 grams of *Semen armeniacae amarum* (Ku Xing Ren), 24 grams of *Gypsum fibrosum* (SSG) and 6 grams of *Radix glycyrrhizae* (GC). The distinguished dynamic biomolecule was ephedrine glycyrrhizic acid, and the examination proposed that it controls the coagulation framework in the inflammatory storm, caused in the by COVID-19, and the unfavorable responses are not yet characterized [94].

Then again, the Chinese government included TCM (Traditional Chinese Medicine) as one of the suggested restorative alternatives for COVID-19 treatment in the third version of COVID-19 treatment guidelines, which was published on January 23, 2020.

The fundamentally suggested formula was QFP (Qingfei Paidu Decoction) composed of more than 120 biomolecules with significant anti-inflammatory impacts, recognized by UPLC, and identifying as the primary dynamic biomolecules to Hesperidin, Astin J, Zingiberoside A, Glycyrrhizic acid, Pogostone, Senkirkine, Ephedrine, Salkosaponin A, Alisol C monoacetate, Balcalin, Irisflorentin, Dioscin, Synepryne, and Apigenin. QFP is compelling for patients at all stages, and the complete effective rate is 92.09% and, an everyday dose is suggested, once toward the beginning of the day and in the evening (40 min after a supper), drink warm water, three dosages as a course [93].

The plan was affirmed in March 2020 by the Guide for the finding and treatment of pneumonia by COVID-19, from the National Health Commission (NHC) of the People's Republic of China, Additionally, the definition was suggested by the Korean rules since

it expands immunology and lessens irritation by focusing on the lung and spleen, which are the disease pathways of COVID-19. Be that as it may, the herb *Farfarae Flos* was taken out because of safety and toxicity issues [95].

XII. ADEQUACY AND ANTAGONISTIC RESPONSE IN THE ADMINISTRATION OF BIOACTIVE SUBSTANCES AGAINST COVID-19

For the administration of bioactive substances, clinical studies are of vital importance and should be upheld by *in silico* and *in vitro* studies. Absolutely, the FDA has endorsed a wide scope of individual biomolecules that they consider protected, every one of them should have opportune clinical preliminaries to characterize their human utilization in the suitable doses, since even quercetin, which is a promising biomolecule against SARS-CoV-2 has a broad metabolism in blood plasma prompting low plasma concentrations and despite the fact that quercetin in a 10 mL nasal portion of ~ 76 µg has been suggested. The therapy with this biomolecule ought to be cautious on account of existing lung cancer [96].

On the other hand, there are several dynamic rules that have been tried in TCM. Glycyrrhizic acid (GA) is a biomolecule that has been appeared to have an impact *in silico*. Moreover, it has shown anti-inflammatory effects in humans and antiviral effects against SARS and has been proposed to be proposed against COVID-19. GA is viewed as a medication with a good economic and safety profile. Nonetheless, at a dose of 200 mg, it reaches at a greatest level in plasma of 80 µg/mL, which doesn't permit the ideal natural impact. To build its adequacy, primary changes have been thought of, yet may bring about more prominent cytotoxicity [89].

Another normal item that has been proposed for the treatment of COVID-19 is propolis, which is a natural item created by honey bees, formed principally by polyphenolic components. Preclinical investigations have shown that propolis advances the immunoregulation of favorable to inflammatory cytokines, including the decrease of IL-6, IL-1 beta and TNF-α, lessening the risk of cytokine storm disorder, a significant mortality factor in cutting edge COVID-19 [97].

The dosage relies upon the standardization, and normally the propolis may have differences because of the raw material, which relies upon the environment. In any case, there is a patent considered EPP-AF® that has reproducibility and the clinical information so far help doses of 375–500 mg of propolis/day [98,97].

Propolis has additionally been demonstrated to be a safe item, however there are still no reports of clinical trials on its treatment against COVID-19. Be that as it may, a clinical preliminary of Brazilian green propolis extricate (EPP-AF®) for the treatment of patients with COVID-19 was recently began in Brazil [97].

XIII. IN SILICO INVESTIGATIONS OF COMPOUND FROM NATURAL PRODUCTS AGAINST COVID-19

In the requirement for fast reactions to battle the pandemic, numerous studies have been published *in silico*, and the examinations study biomolecules potential, for the most part polyphenolic intensifies disengaged from natural items, which can manage the improvement of new medications. Moreover, these molecular coupling studies have recognized biomolecules that repress natural elements for COVID-19 maturation and, for instance, the research for the inhibition of essential viral enzymes helicase, methyltransferase, RNA polymerase, RNA-subordinate RNA polymerase (RdRp), 3 cysteine protease-like chymotrypsin (3CLpro).

In *silico* studies on Neoastilbin, a formulation of 14 regular items, just as Astilbin, comprised of 93 common items, have shown inhibit enzymes, for example, helicase, methyltransferase, RNA polymerase, and RNA-subordinate RNA polymerase (RdRp) in COVID-19 [99].

In this sense, most virtual screening studies search for various molecular targets, including the inhibition of the protein-changing over catalyst angiotensin-2 (ACE2), for instance, propolis has likewise been examined and seen *in silico* and its flavanones show inhibition mechanisms with high binding constants and high binding affinity to ACE2 and serine protease Transmembrane protease, serine 2 (TMPRSS-2). This component includes overexpression of Serine/threonine protein kinase (PAK1), which is a kinase that intervenes Covid initiated lung irritation, fibrosis, and immunity system suppression. Moreover, different mixtures present in propolis, for example, rutin, showed an amazing inhibitory potential, trailed by myricetin, phenethyl ester of caffeic acid, hesperetin and pinocembrin [100,97].

Another biomolecule, for example, limonin, quercetin, and kaempferol, normal mixtures in propolis, have been found to repress viral RNA-subordinate RNA polymerase (RdRp) and spike glycoprotein (SGp), and their impact is acting viral inhibitory potential in the segment that clings to the host cell with high binding energy to viral segments from – 9 to – 7.1 kcal/mol [97]. Propolis is a significant helpful alternative, protected, simple to oversee orally and promptly accessible as a characteristic enhancement and

useful food, and thought about GRAS (by and large perceived as protected) by the FDA; just as rutin usually found in food sources like tomatoes and furthermore some *in silico* contemplations show, for example, rutin, have preferable binding energy over the hydroxychloroquine and remdesivir drugs against COVID-19 [101,98]. In any case, albeit *in silico* considerations have recognized the most encouraging biomolecules against SARS-CoV-2, for example, rutin, most researchers reason that *in vitro* and *in vivo* studies are needed to check such antiviral impacts. Then again, numerous herbs, for example, the ones depicted in this audit are not dispersed worldwide and taking into account the direness for a powerful treatment, reciprocal treatments are required, and consequently, today numerous patients use it to complement western medication.

XIV. DIAGNOSTICS AND SURVEILLANCE OF COVID-19

Because of the high individual to-individual transmission rate of SARS-CoV-2, even from asymptomatic transporters, notwithstanding the complexity of the progression of the disease among suggestive people, the wellbeing area has been compelled to have nonstop indicative conventions that precisely distinguish new cases, with the expectation of setting up satisfactory moderation methodologies trying to hinder or decrease consistent spread. Moreover, early conclusion of viral disease after indications beginning, however before confusions, and opportune antiviral restorative intercession is seen as a basic determinant of the successful result of most medications tried to date [56]. Then again, surveillance following the prevalence of the current and past SARS-CoV-2 infections through seroconversion is amazingly useful at directing general wellbeing strategy choices. What's more, seroconversion ID of active cases and recovering people through population-wide surveillance additionally gives important information to observing the achievement and restrictions of prospect prophylactic immunization base technique at decreasing susceptibility and transmission, just as assessment of promising antiviral medications with wide reach adequacy and disease progression. In like manner, finding of COVID-19 from upper respiratory track swabs has utilized old style molecular and serological methods, adjusted to identify special SARS-CoV-2 genomic arrangement fingerprints through real-time reverse transcriptase polymerase chain response (RT-PCR) amplification, just as the presence of unique surface exposed molecular distinctive antigens, individually. Early months of the pandemic, active case distinguishing proof and surveillance was performed by Lab-based atomic RT-PCR tests, utilizing a several sets of preliminaries from various arrangements of SARS-CoV-2, contingent upon the country of origin of the test [28]. One significant test for these tests was the ideal opportunity for results return; albeit right now monetarily accessible units, for example, COVID-19 Home Test Kit from Carbon Health or Roche Cepheid EXpert Xpress, offer outcomes as ahead of schedule as 3 h [102]. In the course of the most recent many years, biotechnological progresses in molecular science have made conceivable the advancement of fast tests, for example, loop mediated isothermal enhancement (LAMP), following an underlying RTamplification step. A promising commercial LAMP-based fast detection test, ID NOWTM COVID Test created by Abbot's Binaxx, got emergency use approval by the USA-FDA in July given its quick outcome returns of as ahead of schedule as 5 min for positive outcome and 13 for negative outcomes [103]. A new report by [102] showed that ID NOW test has comparable affectability and particularity of the outcomes as Lab-based RT-PCR tests however just for patients with high viral burden on bodily fluid examples; regardless, the creators contend that infection could in any case be communicated from undetected infected individuals. An elective methodology under investigation are Aptamers, a pool of oligonucleotides, or even small peptide particles, and first revealed in 1990 [104]. Aptamers can be adjusted and blended for various targets, including SARS-CoV-2, they are quick recognition strategies (results inside couple of moments), with no past planning step of tests [105]. Ongoing work is on course, for the advancement of a SARS-CoV-2 aptamer-based point of utilization rapid detection device. At last, Next-Generation Sequencing (NGS), Micro-array, and recently, an assortment of nanotechnology-based techniques is quickly being created, since nanomaterial-based strategies are demonstrated appropriate for fast discovery [106]. New generation of biosensors is in the pipeline. field-effect transistor (FET)-based biosensor, for quick identification of the SARS-CoV-2 infection, thinking about that RT-PCR, the essential technique for COVID-19 finding, takes in any event 3 h to execute, including viral RNA planning, step that can influence analytic precision. Among the benefits of FET-based biosensors, is the capacity to quantify limited quantities of analytes, with high affectability and immediate estimations.

Endeavors to grow high sensitivity and specificity antigen-detection tests incorporate the SARS-CoV-2 anti-S protein antibody response conjugated to a graphene sheet [63] as a detecting region, with no quantifiable cross-reactivity with antigens from MERS-CoV, effectively distinguishing the virus in clinical cases, segregating among patient and normal samples, with no sample preprocessing and high sensitivity. Distinctive Au NP-based nanomaterials are additionally possibility for dynamic case recognition; Au NPs and quantum dots (QDs) are viewed as key segments for the advancement of improved novel nanotechnology-based discovery frameworks [53]. Among these, is the chiral Au NP-quantum dot nanocomposites [107], consolidating viral lipid tails,

which demonstrates to advance wrap accumulation and break. Another procedure under examination are carbon cathodes adjusted with Au NP, utilizing a recombinant spike protein SI as a biomarker [108].

Seroconversion conclusion of active cases suffers from the low sensitivity (30%) detection of IgM and IgG antiviral antiviral present in generally individual < 7 days of symptoms beginning [109]. In any case, a similar report tracked down that 93.1% of COVID-19 patients showed the presence of discernible degree of neutralizing IgM and IgG antibodies 11 and 14 days after manifestations beginning, separately. In this way, despite the fact that identification of antiSARS-CoV-2 antibodies may not be important as a precise demonstrative tool for active cases, checking seroconversion has gotten pertinent for appraisal of disease progression and infection predominance observation among gaining strength people in a populace. Most serological tests are aimed at identifying heterologously communicated viral primary antigens, including nucleocapsid, framework protein, and essentially S-glycoprotein [22]. In any case, it is imperative to specify that epidemiological observation however seroconversion may be little the commonness of SARS-CoV-2 in the individuals, as a new report discovered extremely low steadiness of flowing antiviral antibodies at a perceivable focus following a very long time after virus exposure, particularly on people who didn't need hospitalization [110]. weather re-infection in recovering individual with low antiviral antibody concentration stays to be resolved.

XV. CONCLUSION

Until now, prophylactic and therapeutic intervention on COVID-19 has had restricted achievement. Large numbers of the most encouraging referred to drugs repurposed as antiviral to treat SARS-CoV-2 disease were found to have restricted antiviral activity, and some created critical hazardous cardiovascular issues, which have brought about suspension of administration. Nucleoside-analogs that focus on the viral replication complex, specifically viral RdRpol, have all the earmarks of being the most encouraging other option, which in mix with the exploratory medication remdesivir show a decrease in hospitalization time and severity of side effects related to COVID-19 disease. biological compounds, like plasma from recovering patients, containing neutralizing antibodies which can block viral passage to cells of susceptible patients, show a decrease in mortality even among severe cases, in spite of the fact that viability is still to be resolved given the absence of randomized clinical preliminaries. This promising impact of improving plasma has been empowering, as they could anticipate the adequacy of immunizations being planned against COVID-19, particularly in those stages that can get dependable humoral reactions, particularly antibodies coordinated against the RBD site of SARS-CoV-2 S-protein, in everyone. vaccines have shown higher than 90% viability and next to no results among vaccinated people. These promising outcomes have conceded crisis use approval by the FDA of the Pfizer and BioNTech mRNA immunization. Be that as it may, prerequisite of the freezing transportation and capacity of this antibodies takes steps to restrict organization in nations lacking required framework. Hence, elective stages, for example, those dependent on adenovirus are presently under audit for use in circumstances where mRNA antibodies are unrealistic or contraindicated. Despite the achievement of these current intercessions, it is critical to keep up observation of viral hereditary changes that could adjust the serotype, just as medication focused on viral chemicals, prompting safe new strains. Likewise, a portion of the difficulties of this pandemic are the right and opportune conclusion of the infection. Analysis of seroconversion that has been viewed as significant for dynamic in relief methodologies, in any case, it has been demonstrated that they can be little the pervasiveness, then again, biotechnological propels have made it conceivable to confront these difficulties with the generation of molecular techniques, much offer Home Test with quick and profoundly touchy outcomes. In such manner, it will be imperative to proceed with examination on likely use of natural products, particularly those with few effects that could hinder essential viral replication cycles and proteins, that could prompt the plan and advancement of new classes of antiviral drugs.

CONFLICT OF INTEREST

All authors declare no conflicts of interest.

AUTHORS CONTRIBUTION

Authors have equally participated and shared every item of the work.

REFERENCES

- [1] Shi, Yu, et al. "An overview of COVID-19." *Journal of Zhejiang University. Science. B* (2020): 1.
- [2] Zhu, Na, et al. "A novel coronavirus from patients with pneumonia in China, 2019." *New England journal of medicine* (2020).

- [3] Mahase, Elisabeth. "Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate." (2020).
- [4] Chien, Lung-Chang, and Lung-Wen Chen. "Meteorological impacts on the incidence of COVID-19 in the US." *Stochastic Environmental Research and Risk Assessment* 34.10 (2020): 1675-1680.
- [5] Connors, Jean M., and Jerrold H. Levy. "COVID-19 and its implications for thrombosis and anticoagulation." *Blood, The Journal of the American Society of Hematology* 135.23 (2020): 2033-2040.
- [6] Gupta, Aakriti, et al. "Extrapulmonary manifestations of COVID-19." *Nature medicine* 26.7 (2020): 1017-1032.
- [7] Liu, Bingwen, et al. "Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?" *Journal of autoimmunity* (2020): 102452.
- [8] Marietta, Marco, et al. "COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISST)." *Blood Transfusion* 18.3 (2020): 167.
- [9] Pelaia, Corrado, et al. "Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications." *Therapeutic advances in respiratory disease* 14 (2020): 1753466620933508.
- [10] Saha, Abinit, et al. "Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19." *Archives of medical research* 51.6 (2020): 595-597.
- [11] Lan, Jun, et al. "Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor." *Nature* 581.7807 (2020): 215-220.
- [12] Lobo-Galo, Naún, et al. "FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication." *Journal of Biomolecular Structure and Dynamics* (2020): 1-9.
- [13] Tu, Yung-Fang, et al. "A review of SARS-CoV-2 and the ongoing clinical trials." *International journal of molecular sciences* 21.7 (2020): 2657.
- [14] Tu, Yung-Fang, et al. "A review of SARS-CoV-2 and the ongoing clinical trials." *International journal of molecular sciences* 21.7 (2020): 2657.
- [15] Wang, Yanqun, et al. "Kinetics of viral load and antibody response in relation to COVID-19 severity." *The Journal of clinical investigation* 130.10 (2020).
- [16] Dai, Wenhao, et al. "Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease." *Science* 368.6497 (2020): 1331-1335.
- [17] Jin, Yuefei, et al. "Virology, epidemiology, pathogenesis, and control of COVID-19." *Viruses* 12.4 (2020): 372.
- [18] Hillen, Hauke S., et al. "Structure of replicating SARS-CoV-2 polymerase." *Nature* 584.7819 (2020): 154-156.
- [19] Agostini, Maria L., et al. "Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exonuclease." *MBio* 9.2 (2018).
- [20] Angelini, Megan M., et al. "Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles." *MBio* 4.4 (2013).
- [21] Liu, Kui, et al. "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province." *Chin*
- [22] Wang, Manli, et al. "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro." *Cell research* 30.3 (2020): 269-271.
- [23] Ziegler, Carly GK, et al. "SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues." *Cell* 181.5 (2020): 1016-1035.
- [24] Gupta, Suchi, et al. "Mesenchymal stem cell derived exosomes: a nano platform for therapeutics and drug delivery in combating COVID-19." *Stem cell reviews and reports* (2020): 1-11.

- [25] Sun, Xinjuan, et al. "Cytokine storm intervention in the early stages of COVID-19 pneumonia." *Cytokine & growth factor reviews* 53 (2020): 38-42.
- [26] Habib, Heba. "Has Sweden's controversial covid-19 strategy been successful?." *bmj* 369 (2020).
- [27] Corey, Lawrence, et al. "A strategic approach to COVID-19 vaccine R&D." *Science* 368.6494 (2020): 948-950.
- [28] Sullivan, Patrick Sean, et al. "Detection of SARS-CoV-2 RNA and antibodies in diverse samples: protocol to validate the sufficiency of provider-observed, home-collected blood, saliva, and oropharyngeal samples." *JMIR public health and surveillance* 6.2 (2020): e19054.
- [29] Shereen, Muhammad Adnan, et al. "COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses." *Journal of advanced research* 24 (2020): 91-98.
- [30] Zhang, Naru, et al. "Current development of COVID-19 diagnostics, vaccines and therapeutics." *Microbes and infection* 22.6-7 (2020): 231-235.
- [31] Wu, Suh-Chin. "Progress and concept for COVID-19 vaccine development." *Biotechnology journal* (2020).
- [32] Robson, Barry. "Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus." *Computers in biology and medicine* 119 (2020): 103670.
- [33] Yuan, Kehu, et al. "Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein." *Biochemical and biophysical research communications* 319.3 (2004): 746-752.
- [34] Mahase, Elisabeth. "Covid-19: What do we know so far about a vaccine?" (2020).
- [35] Prompetchara, Eakachai, Chutitorn Ketloy, and Tanapat Palaga. "Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic." *Asian Pac J Allergy Immunol* 38.1 (2020): 1-9.
- [36] Cohen, Jon. "Vaccine designers take first shots at COVID-19." (2020): 14-16.
- [37] Liu, Cynthia, et al. "Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases." (2020): 315-331.
- [38] Hegarty, Paul K., et al. "BCG vaccination may be protective against Covid-19." preprint (2020).
- [39] Miller, Aaron, et al. "Correlation between universal BCG vaccination policy and reduced mortality for COVID-19." *MedRxiv* (2020).
- [40] Raw, Isaias. "Developing Countries Can Innovate and Produce Vaccines: The Case of Butantan in Brazil." *Vaccines-the History and Future*. IntechOpen, 2019.
- [41] Folegatti, Pedro M., et al. "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial." *The Lancet* 396.10249 (2020): 467-478.
- [42] Shin, Matthew D., et al. "COVID-19 vaccine development and a potential nanomaterial path forward." *Nature nanotechnology* 15.8 (2020): 646-655.
- [43] Zhou, Yadi, et al. "Artificial intelligence in COVID-19 drug repurposing." *The Lancet Digital Health* (2020).
- [44] Bloch, Evan M., et al. "Deployment of convalescent plasma for the prevention and treatment of COVID-19." *The Journal of clinical investigation* 130.6 (2020): 2757-2765.
- [45] Casadevall, Arturo, and Liise-anne Pirofski. "The convalescent sera option for containing COVID-19." *The Journal of clinical investigation* 130.4 (2020): 1545-1548.
- [46][47]- Cyranoski, David. "WHY EMERGENCY COVID VACCINE APPROVALS COULD POSE A DILEMMA." (2020): 18-19.
- [47] Mullard, Asher. "COVID-19 vaccines buoy hope." *Nat Rev Drug Discov*. <https://doi.org/10.1038/d4157> (2020): 3-020.

- [48] Weiss, Carsten, et al. "Toward nanotechnology-enabled approaches against the COVID-19 pandemic." *ACS nano* 14.6 (2020): 6383-6406.
- [49] Sportelli, Maria Chiara, et al. "Can nanotechnology and materials science help the fight against SARS-CoV-2?" *Nanomaterials* 10.4 (2020): 802.
- [50] Erasmus, Jesse H., et al. "An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates." *Science translational medicine* 12.555 (2020).
- [51] Staroverov, S. A., et al. "Immunostimulatory effect of gold nanoparticles conjugated with transmissible gastroenteritis virus." *Bulletin of experimental biology and medicine* 151.4 (2011): 436.
- [52] Nasrollahzadeh, Mahmoud, et al. "Nanomaterials and nanotechnology-associated innovations against viral infections with a focus on coronaviruses." *Nanomaterials* 10.6 (2020): 1072.
- [53] Chauhan, Gaurav, et al. "Nanotechnology for COVID-19: therapeutics and vaccine research." *ACS nano* 14.7 (2020): 7760-7782.
- [54] Gupta, Suchi, et al. "Mesenchymal stem cell derived exosomes: a nano platform for therapeutics and drug delivery in combating COVID-19." *Stem cell reviews and reports* (2020): 1-11.
- [55] Joyner, Michael J., et al. "Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience." *MedRxiv* (2020).
- [56] Huo, Jiangdong, et al. "Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2." *Nature structural & molecular biology* 27.9 (2020): 846-854.
- [57] Schoof, Michael, et al. "An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation." *bioRxiv* (2020).
- [58] Zhang, Qiangzhe, et al. "Cellular nanosponges inhibit SARS-CoV-2 infectivity." *Nano letters* 20.7 (2020): 5570-5574.
- [59] Van Doremalen, Neeltje, et al. "Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1." *New England journal of medicine* 382.16 (2020): 1564-1567.
- [60] Leung, Wallace Woon-Fong, and Yuen Ting Chau. "Experiments on filtering nano-aerosols from vehicular and atmospheric pollutants under dominant diffusion using nanofiber filter." *Separation and Purification Technology* 213 (2019): 186-198.
- [61] Leung, Wallace Woon-Fong, and Qiangqiang Sun. "Charged PVDF multilayer nanofiber filter in filtering simulated airborne novel coronavirus (COVID-19) using ambient nano-aerosols." *Separation and purification technology* 245 (2020): 116887.
- [62] Palmieri, V., and M. J. N. T. Papi. "Can graphene take part in the fight against COVID-19?" *Nano Today* 33 (2020): 100883.
- [63] Ceylan, Zafer, Raciye Meral, and Turgay Cetinkaya. "Relevance of SARS-CoV-2 in food safety and food hygiene: potential preventive measures, suggestions and nanotechnological approaches." *VirusDisease* 31.2 (2020): 154-160.
- [64] Rosa, Sandro G. Viveiros, and Wilson C. Santos. "Clinical trials on drug repositioning for COVID-19 treatment." *Revista Panamericana de Salud Pública* 44 (2020): e40.
- [65] Riva, Laura, et al. "A large-scale drug repositioning survey for SARS-CoV-2 antivirals." *BioRxiv* (2020).
- [66] Sheahan, Timothy P., et al. "An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice." *Science translational medicine* 12.541 (2020).
- [67] Weston, Stuart, et al. "FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro." *BioRxiv* (2020).
- [68] DeVito, Nicholas J., Seb Bacon, and Ben Goldacre. "Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study." *The Lancet* 395.10221 (2020): 361-369.

- [69] Cai, Qingxian, et al. "Experimental treatment with favipiravir for COVID-19: an open-label control study." *Engineering* 6.10 (2020): 1192-1198.
- [70] Hung, Ivan Fan-Ngai, et al. "Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial." *The Lancet* 395.10238 (2020): 1695-1704.
- [71] Doi, Yohei, et al. "A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19." *Antimicrobial agents and chemotherapy* 64.12 (2020).
- [72] de Salud Pública, Subsecretaría. "Orientaciones para Atención Odontológica en Fase IV COVID-19." Santiago de Chile, Subsecretaría de Salud Pública, Ministerio de Salud, Gobierno de Chile (2020).
- [73] Gordon, David E., et al. "A SARS-CoV-2 protein interaction map reveals targets for drug repurposing." *Nature* 583.7816 (2020): 459-468.
- [74] Alia, Erisa, and Jane M. Grant-Kels. "Does hydroxychloroquine combat COVID-19? A timeline of evidence." *Journal of the American Academy of Dermatology* 83.1 (2020): e33-e34.
- [75] Gupta, Anunay, and Amit Malviya. "Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter." *Postgraduate Medical Journal* (2020).
- [76] Hoffmann, Markus, et al. "Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2." *Nature* 585.7826 (2020): 588-590.
- [77] Ahmed, Mohamed. "Natural compounds from Djiboutian medicinal plants as inhibitors of COVID-19 by in silico investigations." (2020).
- [78] Shannon, Ashleigh, et al. "Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites." *Antiviral research* 178 (2020): 104793.
- [79] Orf, Katharine, et al. "Remdesivir during induction chemotherapy for newly diagnosed pediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection." *British journal of hematology* 190.5 (2020): e274-e276.
- [80] WHO Solidarity Trial Consortium. "Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results." *New England Journal of Medicine* 384.6 (2021): 497-511.
- [81] Villar, Jesús, et al. "Dexamethasone treatment for the acute respiratory distress syndrome: a multicenter, randomised controlled trial." *The Lancet Respiratory Medicine* 8.3 (2020): 267-276.
- [82] McMichael, Temet M., et al. "COVID-19 in a long-term care facility—King County, Washington, February 27–March 9, 2020." *Morbidity and Mortality Weekly Report* 69.12 (2020): 339.
- [83] Sterne, Jonathan AC, et al. "Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis." *Jama* 324.13 (2020): 1330-1341.
- [84] Hassan, Sherif TS. "Shedding light on the effect of natural anti-herpesvirus alkaloids on SARS-CoV-2: a treatment option for COVID-19." (2020): 476.
- [85] Ang, Lin, et al. "Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines." *Integrative medicine research* 9.2 (2020): 100407.
- [86] Newman, David J., and Gordon M. Cragg. "Natural products as sources of new drugs from 1981 to 2014." *Journal of natural products* 79.3 (2016): 629-661.
- [87] Ang, Lin, et al. "Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines." *Integrative medicine research* 9.2 (2020): 100407.
- [88] Bailly, Christian, and Gérard Vergoten. "Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?" *Pharmacology & Therapeutics* (2020): 107618.

- [89] Lobo-Galo, Naun, et al. "Recent biotechnological advances as potential intervention strategies against COVID-19." *3 Biotech* 11.2 (2021): 1-21.
- [90] Luo, Erdan, et al. "Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China." *Chinese medicine* 15 (2020): 1-13.
- [91] Zhong, Linda Li Dan, et al. "Potential targets for treatment of coronavirus disease 2019 (COVID-19): a review of Qing-Fei-Pai-du-tang and its major herbs." *The American Journal of Chinese Medicine* 48.05 (2020): 1051-1071.
- [92] Pan, Xiaoqi, et al. "Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China." *Virus research* (2020): 198057.
- [93] Yang, Rucong, et al. "Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): in silico and experimental study." *Pharmacological research* 157 (2020): 104820.
- [94] Ang, Lin, et al. "Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines." *Integrative medicine research* 9.2 (2020): 100407.
- [95] Williamson, Gary, and Asimina Kerimi. "Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction." *Biochemical pharmacology* (2020): 114123.
- [96] Berretta, Andresa Aparecida, et al. "Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease." *Biomedicine & Pharmacotherapy* (2020): 110622.
- [97] Sivaraman, Dhanasekaran, and Puspharaj selvadoss Pradeep. "Revealing anti-viral potential of Bio-active therapeutics targeting SARS-CoV2-polymerase (RdRp) in combating COVID-19: Molecular Investigation on Indian traditional medicines." (2020).
- [98] Naik, Biswajit, et al. "High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment." *International Journal of Biological Macromolecules* 160 (2020): 1-17.
- [99] [100]- Güler, Halil Ibrahim, et al. "Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19 treatment by Molecular Docking Study." *ScienceOpen Preprints* (2020).
- [100] Adem, Sevki, et al. "Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: an in-silico strategy unveils a hope against CORONA." (2020).
- [101] Hogan, Catherine A., et al. "Comparison of the Accula SARS-CoV-2 test with a laboratory-developed assay for detection of SARS-CoV-2 RNA in clinical nasopharyngeal specimens." *Journal of clinical microbiology* 58.8 (2020).
- [102] Teoh, T. K., et al. "Outcomes of point-of-care testing for influenza in the emergency department of a tertiary referral hospital in Ireland." *Journal of Hospital Infection* 110 (2021): 45-51.
- [103] O'Sullivan, Ciara K. "Aptasensors—the future of biosensing?" *Analytical and bioanalytical chemistry* 372.1 (2002): 44-48.
- [104] Kumar, Ramesh, et al. "COVID-19 diagnostic approaches: different roads to the same destination." *Virusdisease* 31.2 (2020): 97-105.
- [105] Rabiee, Navid, et al. "Point-of-use rapid detection of sars-cov-2: nanotechnology-enabled solutions for the COVID-19 pandemic." *International journal of molecular sciences* 21.14 (2020): 5126.
- [106] Ahmed, Syed Rahin, Éva Nagy, and Suresh Neethirajan. "Self-assembled star-shaped chiroplasmonic gold nanoparticles for an ultrasensitive chiro-immunosensor for viruses." *RSC advances* 7.65 (2017): 40849-40857.
- [107] Layqah, Laila Ali, and Shimaa Eissa. "An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes." *Microchimica Acta* 186.4 (2019): 1-10.

- [108] Zhao, Rongqing, et al. "Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection." *Clinical Infectious Diseases* (2020).
- [109] Bruni, Margherita, et al. "Persistence of anti-SARS-CoV-2 antibodies in non-hospitalized COVID-19 convalescent health care workers." *Journal of clinical medicine* 9.10 (2020): 3188.